V 116517

Drug Profile

V 116517

Alternative Names: V-116517

Latest Information Update: 07 Mar 2016

Price : $50

At a glance

  • Originator Purdue Pharma
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postherpetic neuralgia
  • No development reported Musculoskeletal pain; Pain

Most Recent Events

  • 25 Aug 2015 No recent reports on development identified - Phase-II for Musculoskeletal pain in USA (PO)
  • 01 Apr 2014 Purdue Pharma completes a phase II trial in Postherpetic neuralgia in USA (NCT01688947)
  • 31 Jan 2014 Purdue Pharma completes enrolment in its phase II trial for Postherpetic neuralgia in USA (NCT01688947)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top